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Editorial
Smoking: A Major Roadblock in the Fight Against AIDS
Following recent advances in antiretroviral therapy, people liv-
ing with HIV are expected to have near-normal life expectancy.1 
However, smoking is proving to be a major roadblock in achiev-
ing this goal. Where antiretroviral therapy is available, more life 
years are lost to smoking than to HIV.2 A 35-year-old HIV-infected 
smoker’s life expectancy is 62.6 years compared with 78.4 years in 
an HIV-infected nonsmoker—a loss of 15.8 life years.2 On the other 
hand, male smokers in general population lose an average of 9.2 life 
years.3 This suggests that smoking alone is not responsible for this 
effect and there are other interactions with HIV-related factors.
Smoking leads to substantial morbidity and mortality among 
HIV-infected individuals.4 Smoking impairs T-cell immune activa-
tion and function and together with HIV infection can result in the 
worst immune profile.5 Consequently, the risk of acquiring oral can-
didiasis,6 pneumocystis7 and bacterial pneumonia,4 and tuberculo-
sis7 is enhanced in HIV-infected individuals. Smoking also puts them 
at increased risk of non-AIDS–related conditions such as chronic 
obstructive pulmonary disease, lung cancer, cardiovascular diseases, 
osteoporosis, and human papillomavirus infection and related can-
cers.8 A combination of high smoking prevalence and immune dys-
regulation in HIV-infected people is shown to increase the risk of 
acute coronary syndrome attributable to smoking, which is almost 
double of that of HIV-negative individuals.9
In this issue, Lall and colleagues report an alarmingly high prev-
alence of tobacco use (68%) among HIV-infected men in India.10 
Their secondary analysis of a large-sample national survey provides 
the most representative data so far from India, home to the third 
largest number of HIV-infected people—2.1 million in 2013.11 Their 
findings are consistent with those from previous studies, mostly US 
based, which have reported high smoking prevalence among HIV-
infected people, often two to three times higher than in the general 
population.4 The authors concluded HIV-infected smokers are likely 
to smoke heavily—a finding also reported in previous studies.4 Being 
based on data from a high HIV burden country, the findings of Lall 
and colleagues are more worrisome than those previously reported.
There are many opportunities to offer cessation support to HIV-
infected individuals due to their frequent contact with health care 
professional. Yet many health professionals, despite realizing its 
importance, remain reluctant to offer cessation support to their HIV 
patients.12 Contrary to what one might expect, three-fourths of HIV-
infected smokers are willing to quit and two-thirds have made a pre-
vious quit attempt.13 However, they need intensive cessation support 
due to a number of factors that influence their smoking patterns, 
reduce likelihood to quit on their own, and increase relapse rates 
after quit attempts. These include high nicotine dependency, social 
conditions (eg, deprivation and discrimination), polysubstance use 
(eg, alcohol, cannabis, and cocaine), stress, psychiatric comorbidity, 
morbid beliefs, and other physical symptoms.12 Quitting is likely to 
result in significant health gains, for example, a significant reduction 
in the risk of a cardiovascular event within first 3 years.14
Due to an extraordinary number of HIV-infected smokers and 
their significantly reduced life expectancy, smoking cessation should 
be considered an integral part of HIV treatment plans. A broad con-
sensus on evidence-based approaches to cessation in HIV-infected 
smokers is urgently needed. Policy makers and practitioners need 
to integrate these approaches within HIV programs and clinical 
practice.
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